Topic: commercial manufacturing
Particle Sciences will have commercial manufacturing capabilities operating at its Pennsylvania facility by the end of the year and will add 30 jobs.
Drug-delivery specialist Aptar Pharma is beefing up capacity at a New York plant to bring supplies of a key product closer to U.S. customers.
Takeda is starting work on a €40 million plant to manufacture multiple myeloma drug Ninlaro at its site in Ireland, where it will add 40 new jobs.
Japan’s Sawai is following other drugmakers by establishing a U.S. manufacturing beachhead by acquiring a U.S. generics operation.
India’s Granules bought a U.S. R&D facility in 2014 and is now ready to add manufacturing as part of plans to expand significantly in the U.S. market.
The on-again, off-again $215 million expansion of an Eli Lilly biologics plant in Ireland is on again.
Transdermal patch maker ProSolus Pharmaceuticals two years ago and has now more than doubled its capacity with a second manufacturing facility in Texas.
A partnership has opened a $53 million, 75,000-square-meter manufacturing facility in Saudi Arabia’s King Abdullah Economic City.
Gilead is building a manufacturing facility in China, its first outside the U.S.
Inksys Therapeutics expands a Texas manufacturing site despite legal turmoil from an indictment claiming its former CEO bribed doctors to prescribe Subsys.